New Delhi, Nov 19 (PTI) A 44-year-old man from Noida, whose tongue cancer recurred despite surgery and radiation therapy, has

New Delhi, Nov 19 (PTI) A 44-year-old man from Noida, whose tongue cancer recurred despite surgery and radiation therapy, has

New Delhi, Nov 19 (PTI) A 44-year-old man from Noida, whose tongue cancer recurred despite surgery and radiation therapy, has

New Delhi, Nov 19 (PTI) A 44-year-old man from Noida, whose tongue cancer recurred despite surgery and radiation therapy, has achieved a complete response following treatment involving immunotherapy, with the benefits sustained even after a few years, doctors said.

     According to a statement issued by Indraprastha Apollo Hospital, the patient was initially diagnosed with squamous cell carcinoma of the tongue and underwent surgery to remove the affected tissue, followed by radiation therapy. However, the cancer returned, prompting doctors to consider further treatment.

     He subsequently underwent another major surgery involving the removal of a portion of his tongue and lower jaw, followed by reconstructive surgery to restore the affected area.

     A few months later, a swelling near his jaw was found to contain cancer cells. Further investigations revealed that the disease was also affecting the area around the operated portion of the jaw and a nearby gland, the statement said.

     With the cancer recurring despite previous treatment, doctors started him on a combination of chemotherapy and immunotherapy, along with oral medication.

     Immunotherapy, which works by helping the body’s immune system recognise and fight cancer cells, became an important part of his revised treatment plan. As the disease continued to require management, doctors modified the treatment, while continuing immunotherapy, according to the statement.

     A subsequent PET-CT scan showed reduced activity around the operated portion of the lower jaw. Abnormalities previously detected in the lungs and chest lymph nodes were no longer visible, while the changes around the jaw were considered more likely to be associated with inflammation than active cancer, it said.

     The patient achieved a complete response with immunotherapy, with the benefit sustained even after a few years, doctors said.

     Dr Akshat Malik, Senior Consultant and Head of Head and Neck Oncology at Indraprastha Apollo Hospital, said immunotherapy had expanded treatment options for certain cancers, but not every patient was suitable for it and the response could vary.

     In cancers such as head and neck cancer, testing for PD-L1, a protein that influences how cancer cells interact with the immune system, can help doctors assess the likelihood of a response and guide treatment decisions, he said.

     However, the test is only one part of the overall assessment and does not guarantee how a patient will respond to treatment, Malik said.

     The choice of treatment needs to be individualised, taking into account the type and stage of cancer, previous treatments and the patient’s overall condition, he added.

     "What makes this case particularly noteworthy is the complete response achieved with immunotherapy, with the benefit sustained even after a few years. While chemotherapy and immunotherapy are established options in recurrent head and neck cancers, the response is not uniform across patients," doctors said.

     They added that a sustained response over such a period is encouraging, particularly in cases where the disease has recurred despite previous treatment.

     The doctors said it highlights the potential of immunotherapy in achieving durable disease control and the importance of assessing each patient’s response over time. However, treatment outcomes remain individual, and continued follow-up is essential.

(This story has not been edited by THE WEEK and is auto-generated from PTI)